ArticleSAGE open medical case reports2025
Aquaporin-4-positive neuromyelitis optica in a male Caucasian patient: A rare demographic presentation.
Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica with a positive aquaporin-4 antibody is a rare autoimmune condition, which has a higher prevalence in females, and disproportionately affects Black and Asian persons with a typical age of first presentation between the ages of 30 and 40. We report a unique case of a 69-year-old Caucasian male who presented following a fall along with generalised weakness, unilateral myotomal pain, and urinary dysfunction. His medical history included two previous venous thromboembolic events, for which he was anticoagulated with warfarin. Extensive investigations, including MRI of the whole spine and lumbar puncture, revealed longitudinally extensive transverse myelitis and a positive aquaporin-4 antibody, confirming neuromyelitis optica. The patient was treated with intravenous methylprednisolone, plasma exchange, and immunoglobulin therapy, followed by rehabilitation. This case highlights the importance of considering neuromyelitis optica in atypical patient demographics and that early recognition through neurological assessment, imaging, and antibody testing is critical in preventing severe disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.